**SfE Guidance on Adult Growth Hormone (GH) replacement therapy during the COVID -19 pandemic**

The worldwide spread of the novel coronavirus, COVID-19, has recently been declared a pandemic. This presents many challenges to those of us working in healthcare, and will especially impact individuals with some chronic conditions.

Members of the Society for Endocrinology (SfE) have received numerous queries regarding how this pandemic may affect management of adult patients on Growth hormone (GH) replacement therapy, so we have formulated responses to these questions in order to assist our endocrine and primary care colleagues during this extraordinary time. We acknowledge that the situation is changing rapidly and also that local practice may differ depending on available resources and infrastructure.

* **Patients established on growth hormone who are well**
	+ Continue GH replacement as same dose even if no recent IGF-1 level available
	+ If patients prefer to pause their GH replacement or if there is a supply issue, patients can safely pause their GH treatment for the coming months.
* **Patient with suspected or confirmed Covid-19**

Stop GH if patient requires hospital admission and restart when patient has recovered and is asymptomatic from Covid-19

* **New patients with confirmed GH deficiency**

Delay GH initiation to avoid unnecessary travel for blood tests and to avoid starting GH without biochemical and clinical monitoring